Pernix Therapeutics Holdings
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Pernix Therapeutics Holdings whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted. Non-GAAP earnings per share shrank to a loss. GAAP earnings per share dropped to a loss.
Margins dropped across the board.
Pernix Therapeutics Holdings reported revenue of $18.2 million. The six analysts polled by S&P Capital IQ expected a top line of $23.4 million on the same basis. GAAP reported sales were 15% lower than the prior-year quarter's $21.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The six earnings estimates compiled by S&P Capital IQ anticipated $0.03 per share. Non-GAAP EPS were -$0.03 for Q4 versus $0.16 per share for the prior-year quarter. GAAP EPS were -$0.05 for Q4 compared to $0.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 58.7%, much worse than the prior-year quarter. Operating margin was -8.6%, much worse than the prior-year quarter. Net margin was -7.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $28.3 million. On the bottom line, the average EPS estimate is -$0.05.
Next year's average estimate for revenue is $119.7 million. The average EPS estimate is -$0.11.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is outperform, with an average price target of $12.40.
- Add Pernix Therapeutics Holdings to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
1 Stock I'm Buying More Of in 2018
One airline stock is trading for less than 7 times trailing earnings -- even though the company is likely to achieve double-digit EPS growth in 2018.
Vermont Is Legalizing Marijuana in a Unique Way
No state has ever done this before, and it could pave the way for other states to follow in its footsteps.
This Top Dividend Growth Stock Sees No End in Sight
After growing its already lucrative payout 30% last year, this 4.6% yielder sees at least 20% annual growth for the next five years.